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The Journal of Immunology
Contribution of Myelin Autoantigen Citrullination to T Cell
Autoaggression in the Central Nervous System
Antonio Carrillo-Vico,1 Melanie D. Leech, and Stephen M. Anderton
Breakdown in immunological self tolerance, leading to autoimmune diseases such as multiple sclerosis, might arise from immune
recognition of self proteins that have undergone heightened posttranslational modification under pathophysiological conditions. A
posttranslational modification of particular interest is the deimination of Arg to citrulline, catalyzed by peptidylarginyl deiminase
(PAD) enzymes. As a CD4+ T cell-driven model of multiple sclerosis, we used experimental autoimmune encephalomyelitis (EAE)
induced with the immunodominant 35–55 peptide of myelin oligodendrocyte glycoprotein (pMOG) in C57BL/6 mice to test
whether citrullination of a T cell epitope can contribute to disease etiopathology. Immunization with an altered peptide ligand
(APL) of pMOG with an Arg→citrulline conversion at a TCR contact (residue 41) led to the activation of two populations of APL-
responsive T cells that either did, or did not cross-react with the native pMOG peptide. This APL could induce EAE. However,
this reflected the activation of T cells that cross-reacted with the native pMOG epitope, because prior tolerization of these T cells
using pMOG prevented APL-induced EAE. Using a passive transfer model, we found that T cells that responded specifically to the
citrullinated form of pMOG were neither necessary, nor sufficient to initiate the EAE lesion. Nevertheless, these cells could
provoke exacerbation of pathology if transferred into mice with ongoing EAE. The PAD2 and PAD4 enzymes were markedly
upregulated in the inflamed CNS. Therefore, once inflammation is established, citrullination of target autoantigens can allow an
expanded repertoire of T cells to contribute to CNS pathology. The Journal of Immunology, 2010, 184: 2839–2846.
A
lthough the mammalian genome encodes only 20 amino
acids, analyses of mature proteins have identified .100
diverse amino acids (1). These arise from post-
translational modifications (PTM) that can occur spontaneously
(2), or as a result of enzymatic activity. The de novo recognition of
self-Ags that have been modified as a result of pathophysiological
disturbance (3, 4) is an appealing basis for breakdown in immu-
nologic self tolerance; namely, the immune system would target
the modified self-Ag as if it were pathogen derived. The literature
provides various examples of Ab- and/or T cell-reactivity against
antigenic epitopes that contain PTM such as glycosylation, dea-
midation, and citrullination (5–8). Citrullination, the deimination
of Arg to citrulline (Cit) (9), has received particular interest as an
autoantigen modification. This reaction, by which the imino group
of the protein arginyl residues is removed giving rise to Cit, is
catalyzed by a family of calcium-binding enzymes termed pepti-
dylarginine deiminases (PADs; 3.5.3.15). A set of paralogous
genes encode five PAD isoforms in mammals, Pad1–4 and -6,
which have a tissue-specific expression as well as substrate
specificity. Expression of PAD1, PAD3 and PAD6 appears tightly
restricted (10), whereas PAD4 is expressed in monocytes and
granulocytes and PAD2 can be found in the CNS (11, 12). The
association between citrullination and rheumatoid arthritis (RA)
appears well established. Both PAD2 and PAD4 are elevated in
inflamed joints (13), autoantibodies are found that specifically
recognize citrullinated self-proteins (14), and a citrullinated form
of type II collagen (CII) displayed enhanced arthritogenicity in
rats (15). Citrullinated self-peptides have been shown to display
enhanced binding to RA-associated HLA-DR4 molecules (16) and
DR4 transgenic mice can develop arthritis after immunization
with citrullinated, but not unmodified, fibrinogen (17).
Interest in citrullination inmultiple sclerosis (MS) first developed
fromstudies showing increasedcitrullinationofmyelinbasicprotein
(MBP) in patients, and particularly in the hyperacute Marburg’s
syndrome (18, 19). MS patients have been reported to show en-
hanced T cell reactivity to citrullinated MBP leading to the sug-
gestion that this may contribute to disease induction or perpetuation
(20). This has prompted some studies on the contribution of cit-
rullination to pathogenesis of the primary preclinical model forMS,
experimental autoimmune encephalomyelitis (EAE). Citrullinated
MBP is encephalitogenic in both rats and mice (21, 22). Within the
CNS, PAD2 has been found in oligodendrocytes, microglia, and
astrocytes (12, 23, 24) providing the opportunity for modification of
myelin autoantigens. Immunohistochemical analyses revealed that,
although citrullinated proteins were not readily detectable in the
healthy CNS, these were clearly evident in mice with EAE (25, 26).
SJL/J mice with chronic EAE induced by immunization with
a proteolipid protein peptide mounted autoantibody responses
against citrullinated MBP (27). However, although autoantibodies
may contribute to pathology, EAE is primarily driven by the actions
of proinflammatory CD4+ T cells reactive against myelin. Thus far,
no analysis of the contribution of T cells recognizing citrullinated
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myelin Ags has been performed in EAE. In this study, we describe
the contribution of T cells recognizing citrullinated forms of
the immunodominant 35–55 peptide of myelin oligodendrocyte
glycoprotein (hereafter referred to as pMOG).
Materials and Methods
Mice, Ags, and immunizations
C57BL/6 (CD45.1+ or CD45.2+) mice were bred under specific pathogen-
free conditions at the University of Edinburgh. The 6–8-wk-old sex-
matched mice were used for all experiments. pMOG (MEVG-
WYRSPFSRVVHLYRNGK) and the pMOG(41Cit), pMOG(46Cit), and
pMOG(41,46Cit) APL were obtained from Peptide 2.0 (Chantilly, VA).
Mice were immunized with 100 mg peptide emulsified in CFA (Sigma-
Aldrich, Poole, U.K.). A total of 100 ml emulsion was injected s.c., 50 ml
into each hind leg. Primed lymphoid populations were derived either from
spleens or from draining inguinal and para-aortic lymph nodes at the in-
dicated time. Active and passive EAE were induced using previously de-
scribed protocols (28, 29) Clinical signs of EAE were assessed daily with
the following scoring system: 0, no signs; 1, flaccid tail; 2, impaired
righting reflex and/or gait; 3, partial hind limb paralysis; 4, total hind limb
paralysis; 5, hind limb paralysis with partial front limb paralysis; and 6,
moribund or dead. Tolerance was induced by injection of 200 mg peptide
in 0.2 ml PBS i.v. at the indicated time before immunization. All experi-
ments were approved by the University of Edinburgh ethical review panel
and were conducted under United Kingdom legislation.
Spleen recall responses
Spleen cell suspensions were cultured in 96-well flat-bottom microtiter
plates (Becton Dickinson, Oxford, U.K.) at 8 3 105 splenocytes/well using
X-vivo 15 serum-free medium (BioWhittaker, Maidenhead, U.K.) supple-
mented with 2 mM L-glutamine and 53 1025 M 2-ME (all from Invitrogen,
Paisley, U.K.). Cultures were stimulated with a dose range of peptides for 48
h prior to addition of [3H]dThd (0.5 mCi/well) (Amersham, Amersham,
U.K.). After an additional 18 h, dThd incorporation was measured using
a liquid scintillation b-counter (LKB Wallac, Turku, Finland). Results are
expressed as mean cpm of triplicate cultures. Supernatants from similar 72 h
cultures were tested for IFN-g and IL-17 production by ELISA.
PAD2 and PAD4 mRNA expression
TotalRNAfrombrainand spinal cordor lymphnodeand spleenwasextracted
using RNeasy Lipid Tissue Mini Kit or RNeasy Mini Kit (Qiagen, Hilden,
Germany), respectively. Single-strand cDNAwas then synthesized from1mg
RNA according to the Cloned AMV First-Strand cDNA Synthesis Kit
(Invitrogen). Real-time quantitative PCR was performed by the Chromo4
real-time system (MJ Research, Waltham, MA). Reactions were performed
in a 50 ml volume containing 10 ml RT product as template DNA (100 ng),
23 Platinum SYBR Green quantitative PCR SuperMix-UDG (Invitrogen),
and 200 nM for each primer set. AUDG incubation step before PCR cycling
was carried out to destroy any contaminating dU-containing product from
previous reaction. UDG was then inactivated by the high temperatures
during the first PCR step (95˚C for 2 min.). After that, a denaturation (95˚C
for 15 s), annealing (60˚C for 30 s) and extension (72˚C for 15 s) steps were
repeated 30 times with fluorescent data acquisition after each extension step.
Finally, a melting curve program from 60˚C to 95˚C, followed by a cooling
step at 20˚C were performed. Primers (59 to 39): Pad2 (241-bp product): 59
TAC AGC AAG CAA GAC CTC CA 39 (exon 6) and 59 CCA CGA AGA
ACAGCAACT CC 39 (exon 7); Pad4 (217 bp product): 59GCT GCC TGT
GGT CTT TGACT 39 (exon 9) and 59 GTA ACC GCTATT CCC GAT GA
39 (exon 11). All reactions were performed in triplicate. The hprt gene was
used as the control for the calculation of DCt. Analysis of relative gene
expression was determined by evaluating the expression of 22DDCT.
T cell hybridomas
Draining lymph node populations were stimulated in vitro with 10 mM
peptide for 3 d and blasts were then fused with the TCR-deficient BW5147
thymoma as described previously (30). All hybrids were cloned and re-
cloned by limiting dilution. IL-2 production in response to 24-h culture
with peptide presented by irradiated (30 Gy) syngeneic splenocytes was
determined by ELISA.
CNS-infiltrating mononuclear cells
Mice were perfused with cold PBS, brain and spinal cords were removed,
digested, and mononuclear cells retrieved from a 30%:70% discontinuous
percoll gradient as described previously (28).
Flow cytometry for surface phenotype and intracellular
cytokine staining
Cells were stained for FACS using the following Abs and reagents: anti–
CD4-AlexaFluor 700/allophycocyanin/PE/PerCP (BD Pharmingen, San
Diego, CA), anti–CD45.1-biotin, anti–IFN-g–FITC, anti–IL-17 PE, rat
IgG1 FITC, rat IgG1 PE, and streptatividin-PerCP (eBioscience, San
Diego, CA). TCRVb usage by hybridomas was assessed using a panel of
anti-VbAbs (BD Pharmingen). FACS data were collected on a LSR II flow
cytometer (BD Biosciences), and data were analyzed using FlowJo soft-
ware (TreeStar, Ashland, OR). For intracellular cytokine staining, cells
were cultured at 1 3 107 cells/ml in the presence or absence of 5 mM
peptide. After overnight culture, 1 mg/ml brefeldin A (eBioscience) was
added for the last 4 h of culture. Cells were permeabilized, stained, and
fixed as previously described (29).
Results
The core epitope of pMOG has the potential to be citrullinated
at two TCR contact residues
A series of studies, including our own, have characterized T cell
recognition of pMOG in C57BL/6 mice (30, 31). The core epitope
lies within residues 40–48 (31) and a combination of MHC-
binding studies and analyses of T cell responses to altered peptide
ligands (APLs) have defined MHC- and TCR-contact residues (32,
33). As shown in Fig. 1A, and prompting this study, both residues
41Arg and 46Arg are available for TCR recognition, providing the
opportunity for PAD-mediated deimination to Cit at either or each
of these residues, thereby modifying T cell recognition of MOG.
We therefore synthesized three APLs based on the pMOG se-
quence to provide pMOG(41Cit), pMOG(46Cit), and pMOG
(41,46Cit) (Fig. 1B) for analysis of their biological function.
PAD2 and PAD4 are upregulated in the inflamed CNS
If citrullination of native MOG was to play any role in the path-
ogenesis of EAE, we would expect to find expression of the PAD2
and/or PAD4 enzymes within the CNS, and perhaps particularly
within the inflamed CNS. Quantitative RT-PCR revealed that ex-
pression of PAD2 was elevated in mice with EAE, compared with
healthy control mice, specifically within the CNS and not in the
spleen (Fig. 2A–C). In contrast, PAD4 was upregulated in mice
with EAE in all organs tested, and in the CNS this appeared most
marked in mice with higher clinical scores (Fig. 2D–F). We
FIGURE 1. Citrullination of pMOG TCR contact residues. A, In-
teraction of pMOG with I-Ab and TCR, based on previous studies (30–33).
B, WT pMOG peptide and APLs used in this study.
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therefore concluded that there was the opportunity for MOG to be
citrullinated within the CNS during the inflammatory process that
drives EAE. PAD2 may be most important within the CNS, be-
cause mice specifically lacking this isoform have been previously
shown to have greatly reduced expression of citrullinated proteins
in the CNS (34).
Citrullinated APLs are immunogenic
Our next question was whether the mice could mount a T cell
response against the citrullinated APLs. Analysis of splenocyte
responses from mice immunized against wild-type (WT) pMOG
revealed that both the pMOG(41Cit) and the pMOG(46Cit) APLs
were functional as weak agonists, with the pMOG(41Cit) APLs
being the strongest of these (Fig. 3A–C). In contrast, the pMOG
(41,46Cit) APL behaved essentially as a null peptide, failing to
trigger any clear recall response from pMOG-primed cells. All
three APLs were effective immunogens. However, only immuni-
zation with either the pMOG(41Cit), or the pMOG(46Cit) APL
[and not the pMOG(41,46Cit) APL] could prime an immune
population capable of responding to the WT pMOG peptide (Fig.
3D–L). Consistent with its higher antigenicity on cells primed
against pMOG, the pMOG(41Cit) APL provided a population
with stronger responsiveness for pMOG than did the pMOG
(46Cit) APL. Notably, pMOG-driven production of effector cy-
tokines (IFNg and IL-17) was more evident in pMOG(41Cit)-
primed populations (Fig. 3E–F). The conclusion from these
polyclonal analyses was that immunization either with the WT
pMOG peptide, or with the pMOG(41Cit) APL would effectively
prime a population that contained T cells with some degree of
cross-reactivity against the other peptide. This conclusion was
supported by a clonal analysis of CD4+ T cell hybridomas (using
IL-2 production as a measure of TCR stimulation of the hybrid-
omas). This showed that ∼10% of hybridomas that were raised
against pMOG would respond to pMOG(41Cit), and vice versa
(Fig. 4). A previous study of TCR usage by pMOG-reactive
T cells has shown that around 50% express TCRVb8.1/2, with the
“public” TCR rearrangement using Vb8.2-Jb2.1 (35). Serological
analysis of our two panels of T cell hybridomas revealed that 42%
of those primed with pMOG used Vb8 (11/26), whereas only 18%
of pMOG(41Cit)-primed hybridomas (4/22) used Vb8 (Fig. 4B).
Therefore, after immunization with pMOG(41Cit), there was
a dominant population of T cells that responded only to pMOG
(41Cit), but there was also a small fraction that could cross-react
against native pMOG.
Immunization with pMOG(41Cit) can initiate EAE, but this
requires cross-reactive T cell recognition of noncitrullinated
pMOG
Our next step was to test whether immunization with either of the
APLs could induce EAE. Totally consistent with the data described
previously, it was only the pMOG(41Cit) APL that could re-
producibly provoke an encephalitogenic response, giving an
equivalent incidence to that seen with the WT pMOG peptide, al-
though the severity of the disease attained was significantly lower
(Fig. 5A). Analysis of recall responses from the CNS revealed ef-
fector responses (IFN-g staining) against both pMOG(41Cit) and
pMOG in those mice immunized either with pMOG, or with pMOG
(41Cit) (Fig. 5B). Interestingly, in pMOG-immunized mice, the
response to pMOG(41Cit) appeared to be concentrated in the in-
flamed CNS and could not be detected in the spleen (Fig. 5B),
suggesting that PAD-mediated citrullination of MOG specifically
within the CNS was providing a target for these T cells. The fre-
quencies of IL-17+ cells were always lower, but followed the same
patterns of responsiveness as found with IFN-g (data not shown).
From the previously described data, we could not tell whether
those T cells that could recognize native pMOG were required for
the initiation of the EAE lesion, or whether those cells that spe-
cifically recognized only the citrullinated form of MOG could do
this. We tested this by tolerizing mice either against WT pMOG or
against pMOG(41Cit) by i.v. injection of peptide in saline, prior to
immunization with pMOG(41Cit). This tolerance protocol is
demonstrated to lead to deletion of peptide-reactive T cells (36) and
prevented the development of EAE in each of the tolerized groups
(Fig. 6A). This indicated that the response to the WT peptide was
required to initiate EAE; namely, the group tolerized against
pMOG could only mount a (noncross-reactive) response to pMOG
(41Cit) after immunization with the APLs but did not develop
disease. Those mice tolerized against pMOG(41Cit) also did not
develop disease, indicating the need for activation by the APL to
provoke the cross-reactive response against pMOG. In the reverse
experiment, mice pretolerized against pMOG(41Cit) were fully
susceptible to EAE induced with pMOG (Fig. 6B), underlining
that a response to citrullinated MOG in vivo was not required for
EAE induction. Furthermore, passive transfer experiments re-
vealed that disease could only be transferred using lymph node
populations from mice immunized with pMOG. This required
their reactivation in vitro with pMOG. If the same lymph node
populations were triggered in vitro with pMOG(41Cit), they were
unable to transfer disease (Fig. 6C, 6D).
T cells recognizing citrullinated pMOG can contribute to
ongoing disease
Our conclusion from the EAE experiments described previously
was that specific recognition of pMOG(41Cit) was neither required
nor sufficient to initiate the EAE lesion. This would be consistent
with our finding that both PAD2 and PAD4 were markedly
upregulated within the CNS of mice with ongoing EAE (Fig. 2);
namely, mice in which the CNS is not already inflamed would
have little or no citrullinated MOG available to act as a substrate
for those T cells that respond only to pMOG(41Cit). However, we
speculated that this upregulation of PAD2 and PAD4, associated
with CNS inflammation, might provide sufficient citrullinated
FIGURE 2. Pad2 and Pad4 are upregulated in the inflamed CNS.
Quantitative RT-PCR for Pad2 and Pad4 mRNA expression was performed
on samples taken on day 12 after EAE induction with pMOG, and on those
taken from healthy control mice (0). mRNA levels were normalized
against those for the hprt housekeeping gene. Data are from triplicate
experiments performed. Statistics (Student t test): a, p , 0.001; b, p ,
0.005; c, p , 0.01; and d, p , 0.05 compared with the control (0) group.
The Journal of Immunology 2841
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MOG to allow T cells recognizing pMOG(41Cit) to contribute to
ongoing pathology. In support of this possibility, analysis of recall
responses of pMOG-immunized mice at the height of EAE had
revealed that T cell reactivity to pMOG(41Cit) could be detected
in the CNS, but not in the spleen (Fig. 5B). To test this, we in-
duced active EAE in CD45.2 mice by immunization with pMOG
and, once the disease was at its height, we transferred CD45.1+
lymph node cells that had been immunized and reactivated with
either pMOG or pMOG(41Cit) (Fig. 7A). Importantly, the donor
mice providing the pMOG(41Cit)-primed cells had been pre-
viously tolerized against pMOG (as described previously) to re-
move responsiveness to noncitrullinated pMOG (Fig. 7B).
Transfer of either pMOG-reactive or pMOG(41Cit)-reactive cells
led to an exacerbation of disease commencing 4–6 d after transfer
(Fig. 7C). This timing fits precisely with our experience of the
time taken for transferred cells to become established in the CNS
(SMA, unpublished). Indeed, either transferred population could
be detected within the CNS of host mice (Fig. 7D). The restim-
ulation protocol used to provide donor cells generates pathogenic
Th1 populations that can be reanalyzed for Ag-reactivity, using
IFN-g production as a readout (37). Importantly, flow cytometric
analysis of Ag-induced CD4+CD45.1+ cell production of IFN-g
showed no evidence that the transferred pMOG(41Cit)-reactive
cells could respond to WT pMOG (Fig. 7E, 7F). Mice that re-
ceived either no cell transfer, or that received OVA responsive
cells, showed no evidence of relapse and therefore had lower
cumulative EAE scores after the day of transfer (Fig. 7G, 7H).
Discussion
Our data indicate that pMOG(41Cit) can be highly immunogenic,
in fact the data suggest that immunization with this citrullinated
form triggers a larger population of T cells than is seen after
immunization with WT pMOG (Fig. 5B). An extrapolation from
this would be that the T cell repertoire is not purged of cells that
can recognize pMOG(41Cit), either during thymic development or
in the periphery, although this possibility requires further explo-
ration. The model that emerges from our data is that the initiation
of EAE requires the activity of T cells that can recognize the
FIGURE 3. Immunogenic properties of citrullinated APL. Mice were immunized with pMOG (A–C), pMOG(41Cit) (D–F), pMOG(46Cit) (G–I), or
pMOG(41,46Cit) (J–L) in CFA. After 10 d, splenocyte recall responses to pMOG and citrullinated APL were measured by proliferation (A, D, G, J) IFN-g
production (B, E, H, K), and IL-17 production (C, F, I, L). Data (mean 6 SEM) are from one of three experiments giving consistent results.
FIGURE 4. Analysis of pMOG and pMOG(41Cit) CD4+ T cell hy-
bridomas. A, Representative response profiles of four hybridomas. B,
Frequency of hybridomas cross-reacting against both pMOG and pMOG
(41Cit) and their TCRVb usage, as assessed by flow cytometry.
2842 T CELL RESPONSES TO CITRULLINATED MOG
 by guest on February 28, 2014
http://w
w
w
.jimmunol.org/
D
ow
nloaded from
 
noncitrullinated form of pMOG in the noninflamed CNS (those
that specifically recognize only pMOG(41Cit) cannot transfer
disease). Once inflammation in the CNS is established, PAD2 and
PAD4 are upregulated, allowing for the citrullination of MOG and
thereby providing an antigenic target for pMOG(41Cit)-reactive
T cells that can exacerbate disease (Fig. 7C). Of note, as exem-
plified in Fig. 4, some T cells primed against pMOG(41Cit)
showed particularly high sensitivity to this form of the epitope,
indicating that they may be particularly damaging if able to re-
spond to citrullinated MOG within the CNS.
The interest in the effects of citrullination of MOG on EAE had
been tempered previously by the report that PAD22/2 mice were
fully susceptible to pMOG induced EAE (34). That study did not
address the role of PAD4, which we find to be also upregulated in
the inflamed CNS. Nevertheless, our data are consistent with the
PAD22/2 study, because pMOG-induced EAE can follow a nor-
mal course in mice that had been tolerized to pMOG(41Cit).
Therefore, our conclusion is that, under normal conditions, T cells
that can specifically recognize a citrullinated form of MOG are
available but they cannot initiate disease. However, once EAE is
underway, they can contribute to sustained pathology, dependent
on PAD2 and/or PAD4 function within the CNS.
The upregulation of PAD2 during EAE was specifically seen in
the CNS and was not mirrored in the lymphoid organs. If we
envision a scenario in which T cells that can recognize citrullinated
autoantigen(s) are primed as a consequence of ongoing in-
flammation it seems that this would most likely occur within the
inflamed CNS itself. There is a precedent for this with recent
reports that epitope spreading during EAE can be driven by Ag
presentation by myeloid dendritic cells specifically within the
inflamed CNS (38, 39).
Beyond functioning as a novel autoantigenic target, citrullination
of TCR contacts within the MOG epitope could conceivably have
had dramatically diverse consequences. There is a long literature on
how exposure to APLs can trigger a variety of functional con-
sequences within T cells both in vitro and in vivo (40). These range
from weak agonist activity, through partial agonist (e.g., induction
of cytokine release without concomitant proliferation) (41), to
TCR antagonist activity (the ability to block TCR signaling even
in the presence of the cognate peptide Ag) (42). We and others
have reported on the use of such APLs to ameliorate EAE (43–
45). Using pMOG-primed T cell lines, we tested our citrullinated
APLs for possible partial agonist, or TCR antagonist activities
in vitro and found no evidence for either (data not shown). Thus,
we conclude that the 41Cit, 46Cit, and 41,46Cit modifications
result in an agonist, a weak agonist, and a null peptide, re-
spectively. A further possibility was that citrullination of MOG
could act as a specific target for T cells with particular functional
characteristics. In particular, we have reported on the remarkable
expansion of Foxp3+ regulatory T cells (Tregs) specifically within
the inflamed CNS that triggers the recovery phase that we see in
pMOG-induced EAE (28, 29). In passively transferred EAE it
seems that these protective Tregs (that are all derived from the
host T cell repertoire) have little if any reactivity to native MOG
(29). Using BrdU incorporation as a measure of Treg activation
(29), we found no evidence that these Tregs were able to specif-
ically recognize either of the citullinated APLs (data not shown).
Although our study did not support either of the possibilities de-
scribed above, it remains entirely possible that in other pathologic
scenarios autoantigen modification could have these effects. Al-
though anti-pMOG Abs are generated after pMOG immunization
(46), our experience is that the titers of these do not correlate with
clinical severity of EAE (SMA, unpublished observations).
Moreover, pMOG-induced EAE develops (and in fact is more
FIGURE 6. pMOG(41Cit)-induced EAE requires T cell recognition of
native pMOG. Mice were either i.v. tolerized with pMOG or pMOG(41Cit)
prior to EAE induction with pMOG(41Cit) (A), or tolerized with pMOG
(41Cit) prior to EAE induction with pMOG (B) (seven mice per group,
pooled from two experiments).C andD, Passive transfer of EAE using cells
from mice immunized with either pMOG or pMOG(41Cit) and reactivated
in vitro as indicated (four mice per group from one of two experiments).
FIGURE 5. pMOG(41Cit) induces active EAE. A, Mice were immu-
nized for EAE induction with the indicated peptide in CFA (disease in-
cidence in brackets). pMOG(41Cit) provoked a significantly less severe
EAE compared with native pMOG (p , 0.05, one-way ANOVA, followed
by Tukey test). B, Spleen and CNS were collected at day 16–18 post-
immunization for in vitro analysis of peptide-induced IFN-g production by
FACS. Data are mean6 SEM from eight individual mice. Iso, cells stained
with the relevant isotype control Ab; Med, cells cultured in medium alone
prior to staining.
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severe) in B cell-deficient mice (47), excluding an obligate role for
autoantibodies in this disease model. It would, however, be of in-
terest to explore the pathogenic consequences of a humoral immune
response specifically to MOG that has been citrullinated, either at
residues 41 and/or 46, or at Arg residues outwith the 35–55 T cell
epitope. This was beyond the scope of this study.
FIGURE 7. pMOG(41Cit)-specific cells can exacerbate ongoing EAE. A, EAE was induced in CD45.2 mice by immunization with pMOG. On day 14,
mice received CD45.1 donor cells that had been primed and reactivated with either pMOG, or pMOG(41Cit). The latter group were from donors previously
tolerized to pMOG. Controls received no cell transfer (injection of PBS alone). B, Responsiveness of transferred cells to pMOG versus pMOG(41Cit)
(assayed on day of lymph node harvesting from donor mice). C, Effects of cell transfer on EAE course. D, Numbers of donor cells in host spleen and CNS
taken 10 d after cell transfer. E, Representative FACS plot illustrating IFN-g production by donor cells sampled from spleen (pMOG(41Cit)-primed donor
cells in response to pMOG(41Cit). F, Analysis of donor cell production of IFN-g in response to pMOG and pMOG(41Cit). Data (mean 6 SEM, four mice
per group) are from one of four experiments giving consistent results. G and H, Cumulative data from four experiments showing the 10 d postcell transfer.
Controls received no cell transfer (injection of PBS alone), or cells from lymph nodes of OVA-immunized CD45.2 mice that had been restimulated with
OVA in vitro prior to transfer. H, Mean cumulative EAE refers to the total disease burden for the 10 d postcell transfer (i.e., the mean is taken from
cumulative scores of individual mice for those 10 d). Figures in parentheses are SEM. p values refer to differences between the indicated group and the no
transfer group (Kruskal-Wallis test). Iso, cells stained with the relevant isotype control Ab; Med, cells cultured in medium alone prior to staining.
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The evidence for a pathogenic role for citrullinaton of auto-
antigens in RA seems beyond doubt (48). Most work in this regard
has focused on humoral immune responses, which are more
straightforward to study. Most compelling is the recent demon-
stration of the ability to initiate arthritis with autoantibodies that
specifically target a citrullinated form of CII (49). Some T cell
studies have been undertaken using citrullinated Ags, however.
Reminiscent of earlier observations in celiac disease showing that
wheat gliadin peptides with Gln→Glu substitutions (mimicking
the natural activity of tissue transglutaminase) had enhanced
binding affinities for celiac disease-associated MHC molecules
(50, 51), citrullinated vimentin peptides showed enhanced binding
to the RA-associated DRB1p0401 molecule (16). However, ele-
vated T cell responses to such peptides have not been reported in
autoimmune arthritis (49). A recent report has described the in-
duction of arthritis (characterized by synovial hyperplasia and
ankylosis, but no gross inflammatory infiltrate) in DRB1p0401
transgenic mice after immunization with a citrullinated form of
human fibrinogen, an autoantigen to which anti-Cit Abs are
commonly found in RA patients (17). Of note, no arthritis was
evident in response to either the noncitrullinated form of human
fibrinogen, or citrullinated mouse fibrinogen. The disease was
associated with the production of anti-Cit Abs and also showed
T cell reactivity to a79–91(84Arg→Cit) peptide of human fibrino-
gen, but not to the native form of this peptide. Residue 84 was
modeled to be a TCR contact residue, but that study did not
provide unequivocal evidence that the T cell response to the cit-
rullinated peptide was required for disease; immunization with the
a79–91(84Arg→Cit) peptide was not arthritogenic (17). The ef-
fects of PTM on T cell reactivity to the autoantigen have been
studied most extensively in CII-induced arthritis, where glyco-
sylation is important (52). In mice expressing either Aq, or
transgenic DR4, the key target for T cells is the 260–270 region.
Galactosylation of residue 264 clearly leads to enhanced T cell
reactivity and this seems to be also the case in RA (53–55). Using
the oxidative environment of inflammation as a starting point,
a previous study examined malondialdehyde-modification of re-
combinant rat MOG and found a more severe form of EAE when
this form of the autoantigen was used in DBA/1 mice (56). The
authors concluded that the most likely basis for this was enhanced
uptake of the modified MOG by APC via scavenger receptors,
rather than any direct effect on TCR recognition.
Others have reasoned that recognition of citrullinated MBP by
T cells fromMS patients might reflect an influence on pathogenesis
(20). Intriguing evidence that peripheral blood T cell responses
from MS patients are more robust when challenged with a cit-
rullinated form of an immunodominant MBP peptide than the
noncitrullinated form have lent some support to this view (57).
Lewis rats have been reported to develop EAE after active im-
munization with a citrullinated form of MBP (21). The im-
munodominant epitope of MBP in this setting (72–85) includes an
Arg at position 76 that acts as a TCR contact residue. Investigation
of the effects of an Arg→Cit substitution at this residue concluded
that this was sufficient to abrogate TCR signaling; a MBP (72–
85)-reactive T cell clone and lymph node cells from MBP (72–
85)-primed rats failed to respond to a 76Cit APL, and vice versa
(58). Importantly, although that previous MBP study suggested the
capacity to prime T cells that would respond only to the citrulli-
nated form of the epitope, the ability of such cells to contribute to
pathology was not determined. In this study, we have used precise
modification of a TCR contact residue within the immunodo-
minant epitope of MOG to provide proof of principle for this, but
only as far as exacerbating established EAE. Nevertheless, it is
conceivable that a pre-established T cell population capable of
recognizing a citrullinated myelin autoantigen could initiate an
autoimmune reaction, if PAD2 and/or PAD4 were upregulated in
the CNS by another inflammatory stimulus. In accord with this
thesis, a concise report has shown how citrullination is a general
phenomenon in the inflamed tissues in several diseases of diverse
cause (3). There are also a wide range of additional PTMs that
might be either triggered or increased under inflammatory con-
ditions (5). The most far-reaching implication of the data pre-
sented in this study is that current strategies aimed at identifying
critical autoantigenic epitopes using the 20 naturally occurring
amino acids may be missing a sizeable “hidden” repertoire focused
on modified forms of the autoantigen. Identification of these rep-
resents a major challenge.
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